全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Venlafaxine-Induced Orthostatic Hypotension in a Geriatric Patient

DOI: 10.1155/2013/761567

Full-Text   Cite this paper   Add to My Lib

Abstract:

Venlafaxine is not usually associated with risk of orthostatic hypotension. A 65-year-old US Caucasian female taking 225?mg/day of venlafaxine extended-release developed symptomatic orthostatic hypotension. The systolic and diastolic blood pressure dropped by 25 and 18?mm Hg, respectively, from supine position to standing position within 3 minutes. The patient was otherwise healthy and the orthostatic hypotension resolved with venlafaxine discontinuation. This was a probable venlafaxine adverse drug reaction according to the Naranjo scale. This case contributes to the scarce literature that indicates that clinicians need to be aware that occasionally venlafaxine can induce clinically significant orthostatic hypotension, particularly in geriatric patients. Our patient did not have orthostatic hypotension when she was taking venlafaxine at 60 years of age in higher venlafaxine doses (300?mg/day) but developed this adverse drug reaction when venlafaxine was restarted at the geriatric age. This case indicates that a history of prior tolerance to venlafaxine does not guarantee tolerance after 65 years of age. If a clinician decides to use venlafaxine in geriatric patients, the clinician should warn the patient about the risk of orthostatic hypotension and consider very slow titration and low doses. 1. Introduction The Consensus Committee of the American Autonomic Society and the American Academy of Neurology [1] defined orthostatic hypotension as “a reduction of systolic blood pressure (BP) of at least 20?mm Hg or diastolic BP of at least 10?mm Hg within 3 minutes of standing.” This consensus definition has recently been updated with minor changes [2]. Orthostatic hypotension can be an adverse drug reaction (ADR) to several antidepressants and antipsychotics. These drugs can cause orthostatic hypotension during the first few weeks of treatment but usually tolerance develops. Thus, the risk for hypotension is one of the reasons that slow titration is recommended for some of these drugs. Orthostatic hypotension is usually explained by the alpha-1 antagonistic properties of some antidepressants and antipsychotics [3]. Among antidepressants, several of the tricyclic antidepressants (TCAs) are potent alpha-1 antagonists, but venlafaxine is usually considered to be lacking in antagonist properties at these receptors [3]. Articles focused on venlafaxine cardiovascular ADRs describe venlafaxine as being prone to cause hypertension, but it is not considered to cause orthostatic hypotension [4, 5]. The blockade of the noradrenergic reuptake transporter explains why

References

[1]  Consensus Committee of the American Autonomic Society and the American Academy of Neurology, “Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy,” Neurology, vol. 46, no. 5, p. 1470, 1996.
[2]  R. Freeman, W. Wieling, F. B. Axelrod et al., “Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome,” Clinical Autonomic Research, vol. 21, no. 2, pp. 69–72, 2011.
[3]  E. Richelson, “Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance,” Journal of Clinical Psychiatry, vol. 64, no. 13, pp. 5–12, 2003.
[4]  J. P. Feighner, “Cardiovascular safety in depressed patients: focus on venlafaxine,” Journal of Clinical Psychiatry, vol. 56, no. 12, pp. 574–579, 1995.
[5]  M. E. Thase, “Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients,” Journal of Clinical Psychiatry, vol. 59, no. 10, pp. 502–508, 1998.
[6]  C. A. Naranjo, U. Busto, and E. M. Sellers, “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981.
[7]  H. S. Duggal, K. Jagadheesan, and H. S. Nizamie, “Venlafaxine—induced orthostatic hypotension,” Indian Journal of Psychiatry, vol. 43, pp. 371–373, 2001.
[8]  E. M. Johnson, E. Whyte, B. H. Mulsant et al., “Cardiovascular changes associated with venlafaxine in the treatment of late-life depression,” American Journal of Geriatric Psychiatry, vol. 14, no. 9, pp. 796–802, 2006.
[9]  C. P. Alderman and M. D. Wiese, “Unexpected orthostatic hypotension with venlafaxine,” Australian Journal of Hospital Pharmacy, vol. 29, no. 4, pp. 215–216, 1999.
[10]  J. E. Mazur, J. D. Doty, and A. S. Krygiel, “Fatality related to a 30-g venlafaxine overdose,” Pharmacotherapy, vol. 23, no. 12, pp. 1668–1672, 2003.
[11]  S. Shi and U. Klotz, “Age-related changes in pharmacokinetics,” Current Drug Metabolism, vol. 12, no. 7, pp. 601–610, 2011.
[12]  G. Trifiró and E. Spina, “Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems,” Current Drug Metabolism, vol. 12, no. 7, pp. 611–620, 2011.
[13]  S. Unterecker, C. Hiemke, C. Greiner, et al., “The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions,” Pharmacopsychiatry, vol. 45, pp. 229–235, 2012.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413